Clinical trial
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients…
NCT00233909 · Kanisa Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00233909 |
|---|---|
| Title | A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia |
| Official title | An Open-Label, Phase I/II Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia |
| Lead sponsor | Kanisa Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid |
| Intervention type | Drug |
| Interventions | Zosuquidar, gemtuzumab ozogamicin |
| Enrollment | 55 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Oct 6, 2005 |
| Last update posted | Apr 1, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: